Published 4 days ago • loading... • Updated 4 days ago

Trial to test mild hyperbaric oxygen therapy during active treatment for aggressive brain cancer

Researchers from Southern Cross University and the Melbourne Integrative Oncology Group launched a clinical study in LISMORE, Australia, investigating whether hyperbaric oxygen therapy can support patients undergoing treatment for high-grade glioma.
Solid tumors, including aggressive brain cancers, are often hypoxic. Because radiotherapy partly relies on oxygen-dependent mechanisms, researchers hypothesize that improving tissue oxygenation could enhance treatment effectiveness while reducing side effects.
Backed by a $1 million philanthropic gift, the trial investigates Mild HBOT at 1.35 ATA, substantially lower pressure than the 2 to 3 ATA used in traditional medical HBOT.
While hyperbaric oxygen therapy dissolves oxygen into bloodstream to reach oxygen-deprived tissues, its use during active cancer treatment remains limited and is not routine oncology care. This study shifts focus to potential supportive use during active therapy.
Professor Jon Wardle, Foundation Director of the National Centre for Naturopathic Medicine at SCU, said the study represents a significant step for evidence-informed integrative oncology. Partnering with MIOG allows investigation in a real-world clinical environment while maintaining research standards.

Insights by Ground AI